This site is intended for healthcare professionals

Sanofi’s avalglucosidase alfa shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease.

Read time: 2 mins
Last updated:17th Jun 2020
Published:17th Jun 2020
Condition: Pompe Disease
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest